Value Analysis of Contrast-enhanced Ultrasound in Evaluating the Efficacy of Liver Cancer Ablation Surgery
Objective To explore the value of contrast-enhanced ultrasound in evaluating the curative effect of liver cancer after thermal ablation.Methods A total of 256 lesions were collected from 200 patients with liver cancer.All patients un-derwent thermal ablation of liver cancer,and the tumor was examined by contrast-enhanced ultrasound and enhanced CT or MRI respectively.The complete ablation rate after operation was counted,and the accuracy,sensitivity and specificity of contrast-en-hanced ultrasound were analyzed based on enhanced CT or MRI,and the differences between contrast-enhanced ultrasound and enhanced CT or MRI in evaluating thermal ablation efficacy were compared.Results One month after ablation treatment,234 of 256 liver cancer lesions were completely ablated and 22 lesions remained after enhanced CT or MRI examination,with a complete ablation rate of 91.41％(234/256).Contrast-enhanced ultrasound showed that 230 lesions were completely ablated and 26 le-sions remained.There was no difference between the two methods(P＞0.05).The postoperative efficacy of 256 lesions was evalu-ated.Contrast-enhanced ultrasound showed that 227 lesions were completely ablated and 7 lesions remained among 234 ablation lesions displayed by enhanced CT or MRI.Contrast-enhanced ultrasound of 22 residual lesions revealed by enhanced CT or MRI showed that 3 lesions were completely ablated and 19 lesions remained.There was no difference between the 2 methods(P＞0.05).Based on enhanced CT or MRI,the accuracy,sensitivity and specificity of contrast-enhanced ultrasound in evaluating the curative effect of patients with liver cancer after thermal ablation are 96.09％,86.36％and 97.01％.Conclusion Contrast en-hanced ultrasound can accurately evaluate the ablation efficacy of patients with liver cancer after ablation,and the evaluation re-sults are consistent with enhanced CT or MRI.It can be used as an effective examination method for follow-up of patients with liv-er cancer.
NETL
NSTL
万方数据
